Advances in Immunotherapy for Hepatocellular Carcinoma

Area of Science:

• Oncology
• Immunology
• Hepatology

Background:

• Immune checkpoint inhibitors (ICIs) represent a promising therapeutic strategy for various cancers, including hepatocellular carcinoma (HCC).
• Unlike targeted therapies, ICIs leverage the host immune system, potentially leading to durable responses and reduced drug resistance.
• However, ICI efficacy is significantly influenced by the intricate tumor immune microenvironment (TIME) of HCC, necessitating a deeper understanding for optimal patient selection and biomarker development.

Purpose of the Study:

• To explore the critical role of the tumor immune microenvironment in hepatocellular carcinoma (HCC) for guiding immune checkpoint inhibitor (ICI) therapy.
• To identify potential biomarkers and therapeutic strategies for enhancing ICI effectiveness in HCC.
• To provide a comprehensive overview of ICI treatment considerations in HCC, encompassing immune subclasses, genetic mutations, and specific etiologies.

Main Methods:

• Review and synthesis of current literature on ICI therapy in HCC.
• Analysis of factors influencing the HCC immune microenvironment, including cellular and humoral components.
• Discussion of specific aspects such as Wnt/β-catenin mutations, non-alcoholic steatohepatitis (NASH)-related HCC, hyperprogressive disease (HPD) mechanisms, and hepatitis B virus (HBV) reactivation.

Main Results:

• The effectiveness of ICIs in HCC is intrinsically linked to the characteristics of the tumor immune microenvironment.
• Classifying HCC cases based on their immune profiles can aid in selecting appropriate immunotherapy strategies.
• Key considerations for ICI treatment include HCC immune subclasses, Wnt/β-catenin mutations, NASH-related HCC, HPD, and HBV reactivation.

Conclusions:

• A thorough understanding of the HCC immune landscape is paramount for successful ICI implementation.
• Tailoring immunotherapy based on individual tumor immunity and specific molecular alterations can improve clinical outcomes.
• Further research into biomarkers and therapeutic combinations is essential for advancing ICI therapy in HCC.